Search
Physostigmine
go.drugbank.com/drugs/DB00981ApprovedIt also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
Sonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalIt was FDA approved in 2015 for the treatment of basal cell carcinoma.
Droperidol
go.drugbank.com/drugs/DB00450ApprovedInvestigationalVet approvedA butyrophenone with general properties similar to those of haloperidol. … It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Products: Xomolix 2,5 mg/ml Injektionslösung, PONVeridol 1,25 mg/ml InjektionslösungAbametapir
go.drugbank.com/drugs/DB11932Approved[L15153] The life cycle of head lice (_Pediculus capitis_) is approximately 30 days, seven to twelve of which are spent as eggs laid on hair shafts near the scalp. … help to curb the development of resistance to this agent.
Ensifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigational[L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be … Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalProphylaxis has also shown to reduce the formation of neutralizing anti-FVIII antibodies, or inhibitors [A31552]. … It is commonly marketed as Elocta or Eloctate for intravenous injection.
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalThese parasites can infect humans following ingestion of larvae in contaminated water or food. … [FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawn[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012. … Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy.
Flavoxate
go.drugbank.com/drugs/DB01148ApprovedIts therapeutic usefulness and its mechanism of action are not clear. … It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]
Products: FLOVOX® 200 MG, BLADURIL ® 200 MGDipivefrin
go.drugbank.com/drugs/DB00449ApprovedWithdrawnDipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
Synonyms: (±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate, 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate